|
|
| VGX
announced key management team promotions and additions
|
Blue Bell, PA – August 1, 2005
– J. Joseph Kim, Ph.D., President and Chief Executive
Officer of VGX Pharmaceuticals today announced several key management
changes and appointments designed to expand the organization as it continues
to meet important milestones.
Ernest Shin, Chief Operating Officer
Ernest E. Shin has been promoted to the position of Chief Operating Officer.
Mr. Shin joined VGX in 2001 as its second employee. Since that time he
has played a significant role in helping Dr. Kim, a co-founder of VGX,
to create, establish and develop the company.
Mr. Shin began his professional career at the Naval Air Warfare Center
Aircraft Division as an Aerospace Engineer and later went on to found
and operate a number of startup operations. He has also served in a variety
of senior finance and management positions in several high tech and pharmaceutical
companies, including Hoffman La-Roche. In these various roles, he developed
comprehensive corporate strategies dealing with operational, marketing
and financial issues.
Mr. Shin received his Bachelor of Science degree in Mechanical/Aerospace
Engineering from Rutgers College of Engineering and his MBA in Finance
and Entrepreneurial Management from the Wharton School.
C. Jo White, M.D., Chief Medical Officer
Dr. White has 18 years of senior level clinical/medical affairs positions
with major pharmaceutical companies including BMS, Wyeth and Merck. Her
experience has been focused in the area of infectious diseases and she
is trained as an Internist and Infectious Disease specialist. Dr. White
has designed and conducted over 40 Phase 1-4 trials, filed several Biologics
License Applications/Marketing Authorization Applications and has obtained
regulatory approval for 5 different vaccines and drugs in both the United
States and Europe.
Dr. White was trained in Microbiology at University of Texas where she
graduated Summa Cum Laude. Dr. White also holds an M.D. from the Baylor
College of Medicine with Alpha Omega Alpha honors.
Bryan B.J. Kim, D.M.D., Director, Corporate Development
Dr. B. J. Kim, D.M.D. has been named Director, Corporate Development.
Dr. Kim has over 8 years of experience as a successful private clinician
and is a respected teacher/researcher.
In addition to his responsibilities with VGX Dr. Kim is also a Clinical
Assistant Professor at University of Pennsylvania, School of Dental Medicine
where he has developed innovative clinical programs and directed important
research projects granted by NIDH in microbiology and immunology.
Dr. Kim holds a Bachelor of Arts degree in Economics and a Bachelor of
Science degree in Biological Science, both from University of California
at Irvine. He also holds a Doctor of Dental Medicine degree from the University
of Pennsylvania.
Robert J. Juba, Director, Manufacturing and Quality
Robert J. Juba has been appointed Director, Manufacturing and Quality.
Mr. Juba has 11 years of experience in the pharmaceutical industry at
Merck & Co. He has managed several contract manufacturing and filling
projects for developmental products (Vaccines for Rotavirus and HIV-1),
led pilot plant operations for research and clinical supply manufacturing,
and provided technical expertise for bacterial vaccine manufacturing.
He has extensive experience in managing cGMP processes and operations.
Mr. Juba holds both Bachelor's and Master's Degrees in Chemical Engineering
from the Massachusetts Institute of Technology.
Cautionary
Factors That May Affect Future Results - Materials in this
Web site contain information that includes or is based upon forward-looking
statements within the meaning of the Securities Litigation Reform
Act of 1995. Forward-looking statements relate to expectations or
forecasts of future events. You can identify these statements by the
fact that they do not relate strictly to historical or current facts.
They use words such as "anticipate," "estimate,"
"expect," "project," "intend," "plan,"
"believe," and other words and terms of similar meaning
in connection with a discussion of potential future events, circumstances
or future operating or financial performance. In particular, these
include statements relating to future actions, prospective products
or product approvals, future performance or results of current and
anticipated products, sales efforts, expenses, the outcome of contingencies
such as legal proceedings, and financial results. Any or all of our
forward-looking statements here or in other publications may turn
out to be wrong. They can be affected by inaccurate assumptions or
by known or unknown risks and uncertainties. Many such factors will
be important in determining our actual future results. Consequently,
no forward-looking statement can be guaranteed, and forward-looking
statements may be adversely affected by factors, including general
market conditions, competitive product development, product availability,
current and future branded and generic competition, federal and state
regulations and legislation, manufacturing issues, timing of the elimination
of trade buying, patent positions, litigations and investigations.
Our actual results may vary materially, and there are no guarantees
about the performance or valuation of VGX stock. It is also important
to read the disclosure notice contained in many of the individual
VGX documents available on this Web site as many contain important
information on such cautionary factors as of the date of the individual
document. We undertake no obligation to correct or update any forward-looking
statements, whether as a result of new information, future events
or otherwise. You are advised, however, to consult any further disclosures
we make on related subjects in our reports. |
About VGX
Pharmaceuticals
VGX Pharmaceuticals is a biopharmaceutical company with product candidates
for the treatment of infectious diseases including HIV, hepatitis C as well
as cancer and inflammatory diseases. The Company’s clinical development
programs include PICTOVIR™ for HIV infection and VGX-410C for chronic
hepatitis C virus infection. In addition, VGX Pharmaceuticals’ therapeutic
platform is designed to advance a strong and continual pipeline of drug
candidates into the clinic with novel product candidates to treat cancer
and inflammatory diseases. The product candidates and technology programs
are protected by the Company’s extensive global intellectual property
portfolio. More information about VGX can be found at www.vgxp.com.
Company Contact:
Kevin W. Rassas
Vice President
Tel 267.440.4208
Fax 267.440.4242
E-mail: Rassas@vgxp.com
www.vgxp.com
|
